The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Implementing bispecific antibodies into community practice: overcoming misconceptions & fears
Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, discusses the common challenges community oncologists face when preparing to administer bispecific antibodies for the first time, highlighting that the main barriers are not just cytokine release syndrome (CRS) or neurotoxicity management, but also a lack of awareness and monitoring capabilities. Dr Graff emphasizes the importance of relying on existing tools and guidelines for CRS management, having a structured monitoring program in place, and seeking help from experienced physicians or other community sites to ensure the safe and effective implementation of step-up dosing. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
